Introduction: Examining the potential impact of anemia treatment on clinical outcomes in anemic cancer patients

Oncologist

Volumn 9, Issue SUPPL. 5, 2004, Pages 1-3

  Hudis, Clifford A ^a   Van Belle, Simon ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anemia; Cancer; Epoetin alfa; Erythropoietin; Fatigue; Hemoglobin; Outcomes; Quality of life; rHuEPO; Treatment; Tumor hypoxia

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANEMIA; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL RESEARCH; CONFERENCE PAPER; FATIGUE; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; TREATMENT OUTCOME;

EID: 10644274470     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90005-1     Document Type: Conference Paper

References (8)

1. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist 2004;9(suppl 5):4-9.
2. Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004;9(suppl 5):10-17.
3. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. The Oncologist 2004;9(suppl 5):18-30.
4. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. The Oncologist 2004;9(suppl 5):31-40.
5. Blackwell K, Gascon P, Sigounas et al. rHuEPO and improved treatment outcomes: potential modes of action. The Oncologist 2004;9(suppl 5):41-47.
6. Mittelman M, Neumann D, Peled A et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
7. Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. The Oncologist 2004;9(suppl 5):48-54.
8. Hudis CA, Van Belle S, Chang J et al. rHuEPO and treatment outcomes: the clinical experience. The Oncologist 2004;9(suppl 5):55-69.